Agios Pharmaceuticals (NASDAQ:AGIO) Shares Up 6.7% – Still a Buy?

Posted by Brian Himes on Oct 21st, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report)’s share price was up 6.7% on Monday. The stock traded as high as $33.19 and last traded at $33.4070. 351,030 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 1,051,051 shares. The stock had previously closed at $31.32.

Analyst Upgrades and Downgrades

AGIO has been the subject of a number of research analyst reports. Citigroup increased their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. HC Wainwright boosted their price target on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, July 30th. TD Cowen raised shares of Agios Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 24th. Truist Financial cut their price objective on Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a report on Wednesday, October 7th. Finally, JPMorgan Chase & Co. boosted their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $41.50.

Read Our Latest Stock Report on Agios Pharmaceuticals

Agios Pharmaceuticals Price Performance

The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -5.23 and a beta of 0.63. The stock’s 50 day simple moving average is $33.20 and its 200-day simple moving average is $32.73.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. As a group, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the transaction, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. This trade represents a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Nykredit A S acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth about $26,000. Quantinno Capital Management LP grew its holdings in Agios Pharmaceuticals by 2.7% in the 1st quarter. Quantinno Capital Management LP now owns 27,591 shares of the biopharmaceutical company’s stock valued at $933,000 after buying an additional 736 shares during the last quarter. AlphaCentric Advisors LLC grew its holdings in Agios Pharmaceuticals by 6.3% in the 1st quarter. AlphaCentric Advisors LLC now owns 13,971 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 830 shares during the last quarter. Quantbot Technologies LP bought a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $43,000. Finally, Integrated Wealth Concepts LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $47,000.

Agios Pharmaceuticals Company Profile

(Get Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.